| Project/Area Number |
25861753
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Functional basic dentistry
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 糖尿病 / 血糖値 / 骨吸収 / ペプチド創薬 / TNF-α / アンタゴニスト / 歯周病 / HbA1c |
|---|
| Outline of Final Research Achievements |
Diabetes mellitus (DM) is involved in periodontal disease. In the periodontal disease treatment, dentists need careful attention whether patient is associated with DM or not. We focused TNF-α which is one of the inflammatory cytokines and is known to be involved in both DM and periodontal disease. We made a hypothesis that the inhibition of TNF-α could lead to the improvements of both diseases. In order to clarify whether the reduction of the TNF-α action could be a therapeutic regimen for treating both diseases, we attempted to administer the TNF-α antagonist peptide W9 to animal disease-model of DM and periodontitis. In results, W9 did not reduce the DM symptoms, but it reduced inflammation and bone resorption. These results suggest that W9 could be a potential therapeutic drug candidate to prevent exacerbation of a disease symptom in the case of DM patients in combination with inflammatory bone diseases such as periodontitis.
|
